Form 4: BridgeBio Pharma Director Sells Shares
Insider Transaction (Form 4)
Jennifer E. Cook, a Director of BridgeBio Pharma, Inc., sold 148,589 shares of common stock on July 9, 2026.
Summary
- Option exercise/conversion: acquired 19,000 Common Stock at $8.45 ($160,550) on July 9, 2026; holds 27,383 after (Direct).
- Option exercise/conversion: acquired 112,422 Common Stock at $29.00 ($3,260,238) on July 9, 2026; holds 139,805 after (Direct).
- Option exercise/conversion: acquired 17,167 Common Stock at $16.75 ($287,547) on July 9, 2026; holds 156,972 after (Direct).
- Open-market sale: disposed of 36,167 Common Stock at $84.00 ($3,038,028) on July 9, 2026; holds 120,805 after (Direct).
- Open-market sale: disposed of 112,422 Common Stock at $90.00 ($10,117,980) on July 9, 2026; holds 8,383 after (Direct).
- Option exercise/conversion: disposed of 19,000 Stock Option (Right to Buy) on July 9, 2026 (Direct).
- Option exercise/conversion: disposed of 112,422 Stock Option (Right to Buy) on July 9, 2026 (Direct).
- Option exercise/conversion: disposed of 17,167 Stock Option (Right to Buy) on July 9, 2026 (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $13,156,008 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Jennifer E. Cook — Director
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-09 | Option exercise/conversion | Common Stock | 19,000 | $8 | $160.6K | 27,383 |
| 2026-07-09 | Option exercise/conversion | Common Stock | 112,422 | $29 | $3.3M | 139,805 |
| 2026-07-09 | Option exercise/conversion | Common Stock | 17,167 | $17 | $287.5K | 156,972 |
| 2026-07-09 | Open-market sale | Common Stock | 36,167 | $84 | $3.0M | 120,805 |
| 2026-07-09 | Open-market sale | Common Stock | 112,422 | $90 | $10.1M | 8,383 |
| 2026-07-09 | Option exercise/conversion | Stock Option (Right to Buy) | 19,000 | — | — | 0 |
| 2026-07-09 | Option exercise/conversion | Stock Option (Right to Buy) | 112,422 | — | — | 0 |
| 2026-07-09 | Option exercise/conversion | Stock Option (Right to Buy) | 17,167 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-09 | Option exercise/conversion (19,000 shares) |
| 2026-07-09 | Option exercise/conversion (112,422 shares) |
| 2026-07-09 | Option exercise/conversion (17,167 shares) |
| 2026-07-09 | Open-market sale (36,167 shares) |
| 2026-07-09 | Open-market sale (112,422 shares) |
| 2026-07-09 | Option exercise/conversion (19,000 shares) |
| 2026-07-09 | Option exercise/conversion (112,422 shares) |
| 2026-07-09 | Option exercise/conversion (17,167 shares) |
Keywords
insider transaction, Form 4, BBIO, BridgeBio Pharma, Inc., bearish, Jennifer E. Cook
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.